Structure-based drug design was exploited in the synthesis of 3-(6-chloronaphth-2-
ylsulfonyl) aminopyrrolidin-2-one-based factor Xa (fXa) inhibitors, incorporating an …

Structure and property based drug design was exploited in the synthesis of
sulfonamidopyrrolidin-2-one-based factor Xa (fXa) inhibitors, incorporating biaryl P4 groups …

Factor Xa, a key serine protease in the coagulation cascade, has attracted a great deal of
attention as a target for developing new antithrombotic agents. A series of novel alkyl …

Anthranilamides 4 and 5 were designed and synthesized as selective and orally
bioavailable factor Xa inhibitors. Structural modifications aimed at lowering their lipophilicity …

A novel series of potent and efficacious factor Xa inhibitors which possesses
pyrrole/indole/thiazole moieties as S4 binding element was identified. Compound 7b …

Since Factor Xa (FXa) is well known to play a central role in thrombosis and hemostasis,
inhibition of FXa is an attractive target for antithrombotic strategies. As a part of our …

Factor Xa (FXa) is well known to play a pivotal role in blood coagulation, so FXa inhibitor is a
promising drug candidate for prophylaxis and treatment of thromboembolic diseases. In the …

Since factor Xa (fXa) plays a pivotal role in the blood coagulation cascade, inhibition of fXa
is thought to be an effective treatment for a variety of thrombotic events.(2S)-2-[4-[[(3S)-1 …

Development of new anticoagulants has been in constant demand throughout the world due
to increasing rate of morbidity and mortality caused by thrombotic diseases. Factor Xa (FXa) …

The design and synthesis of a novel class of amino (methyl) pyrrolidine-based sulfonamides
as potent and selective FXa inhibitors is reported. The amino (methyl) pyrrolidine scaffolds …